US · ongoing · ~6 min read
Connecticut v. Sandoz
2026–present · generic dermatology drugs
Connecticut's generic skin-drug case got narrower on September 11, 2026, and several drug claims are still in court.
The story
Connecticut's generic dermatology price case continues against a former Perrigo executive on specific drugs after a September 11, 2026 order dropped other drug claims against him.
Why it matters
States and pharmacies pay generic prices. The surviving claims are about specific dermatology drugs, not every generic the executive ever sold.
What was claimed
The state alleges manufacturers coordinated prices and customers on generic skin drugs.
The other side
A partial dismissal means some drug claims failed. The remaining claims are not admitted.
What it means for you
The September 11, 2026 order narrows the case. It does not set a new pharmacy price.
Bottom line
Connecticut v. Sandoz is still live on the claims that survived September 11, 2026.
Timeline
2026
Record
Connecticut's generic dermatology price case continues against a former Perrigo executive on specific drugs after a September 11, 2026 order dropped other drug claims against him.
Key dates
- Partial summary judgment
- 11 September 2026
Formal snapshot
Summary: Connecticut's generic dermatology price case continues against a former Perrigo executive on specific drugs after a September 11, 2026 order dropped other drug claims against him.
Regulator / plaintiff argument: The state alleges manufacturers coordinated prices and customers on generic skin drugs.
Outcome: Clindamycin, certain Desonide conduct, Econazole, Fluocinonide, and Halobetasol claims remain. Other drug claims against that executive were dismissed.
Conduct tags
Laws referenced
- Sherman Act §1 — 15 U.S.C. §1
Reader signals
0 reads · synced via local demo storage — add NEXT_PUBLIC_SUPABASE_* to enable shared likes and comments
Comments
No comments yet — start the thread.